Bodal Chemicals Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹454Cr
- +7.6% YoY
- +0.7% QoQ
- Net profit
- ₹10Cr
- Turned profitable YoY
- −28.6% QoQ
- Margin
- 10%
- +2 pp YoY
- 0 pp QoQ
Guidance rank: #34 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
Bodal Chemicals Ltd Q1 FY26 key numbers
- Revenue
- Expecting 12%-13% EBITDA margin leading to INR70-80 crores net profit and 7%-8% return on investment.
As stated in Bodal Chemicals Ltd's Q1 FY26 earnings call transcript · published 30 May 2026. Reported figures, not investment advice.
The short version
Company targets to reach INR2,000-2,100 crores revenue in FY27, up from about INR1,900 crores currently. Company targets revenue of around INR1,900 crores for FY26, with a potential upside or downside of 5%.
From Bodal Chemicals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Company targets to reach INR2,000-2,100 crores revenue in FY27, up from about INR1,900 crores currently.
- Expecting 12%-13% EBITDA margin leading to INR70-80 crores net profit and 7%-8% return on investment.
- Growth expected from ramp-up in benzene derivatives and TCCA business volumes in next 3-6 months.
- Benzene derivatives currently at 20%-30% utilization, targeting 70%-80% utilization by Q3/Q4 FY26.
- TCCA market share expected to improve post-import duty clarity, with production resuming as inventory reduces by Q3/Q4.
- Focusing on consolidating existing businesses with limited capex for next 2-3 years, mainly small debottlenecking.
2 more points from Bodal Chemicals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Bodal Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major capex planned in the next couple of years; focus is on consolidating and optimizing the current setup.
- Small debottlenecking or Brownfield expansions may happen but will be very limited in scale.
- Strategic land sale of about 8 acres at Rajpura to a large chlorine consumer to develop pipeline chlorine buyers, not a real estate deal but a business collaboration.
- The company has about 62 acres of surplus land for future expansions, ensuring capacity for growth over the next 10-15 years.
2 more points from Bodal Chemicals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bodal Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Bodal Chemicals Ltd's call on order book
Create a free account to keep reading this call
What the Q1 FY26 call signalled
1 of 4 strong
Bodal Chemicals Ltd — Quarterly revenue & net profit
Bodal Chemicals Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 454 | 422 | +7.6% | 451 | +0.7% |
| Operating profit (EBITDA) | 48 | 34 | +41.2% | 47 | +2.1% |
| Operating margin | 10% | 8% | +2 pp | 10% | 0 pp |
| Profit before tax | 13 | -1 | — | 12 | +8.3% |
| Net profit (PAT) | 10 | -1 | — | 14 | -28.6% |
| EPS (₹) | 0.76 | -0.09 | — | 1.15 | -33.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹863 Cr, net profit ₹81 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bodal Chemicals's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Balaji Amines (Q1 FY26)
Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25…
- Linde India (Q1 FY26)
Net Revenue for FY ended Mar’25 was INR 24,854 million, down 10.2% (–2,833 million) YoY from INR 27,687 million. Key concall takeaways from Linde India Ltd's…
- Vidhi Specialty (Q1 FY26)
87.9 Crores . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Chemcon Speciality Chemicals (Q1 FY26)
Q1 FY26 revenue from operations: ₹53.5 Cr, up 18% YoY from ₹45.5 Cr in Q1 FY25 (Page 7 & 6). Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q1…
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Bodal Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Bodal Chemicals Ltd Q1 FY26 results?
Company targets to reach INR2,000-2,100 crores revenue in FY27, up from about INR1,900 crores currently. Company targets revenue of around INR1,900 crores for FY26, with a potential upside or downside of 5%.
What is Bodal Chemicals Ltd share price analysis?
Bodal Chemicals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 13.8 with a market cap of ₹950 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bodal Chemicals Ltd planning capital expenditure?
No major capex planned in the next couple of years; focus is on consolidating and optimizing the current setup.
Keep Bodal Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
